Citations

Clear

16 citation(s) found for "Li, Yanfeng".

Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells, but likely not autoantibodies 2251377
Yu, Yue, Chen, Shiju, Langenfeld, Hannah, Li, Yanfeng, Wang, Panwen , Li, Ying, Markovic, Svetomir, Davis, John, Crowson, C. S., Thanarajasingam, Uma , Zeng, Hu, Zhu, Xingxing , Langenfeld, Hannah E., Markovic, Svetomir, Davis, John M. , Dong, Haidong , Zeng, Hu

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.111 Get It

Abstract Introduction The underlying immunopathogenesis of inflammatory arthritis (IA) immune-related adverse event (irAE) remains obscure. Unlike rheumatoid arthritis (RA), where autoantibodies and B cell dysfunction are central features, the contribution of humoral immunity to IA-irAE is unclear. Methods Here, we performed immunophenotyping of peripheral blood from IA-irAE patients, and compared them with seronegative RA patients, ICI-treated patients without irAE, and healthy controls. Results IA-irAE was marked with increased cytotoxic gene expression and metabolic activation in T cells, and reduced CXCR3 and CCR6 expression in CD4+ T cells. Contrary to seronegative RA, IA-irAE patients displayed no significant elevation in autoantibody levels or atypical CD11c+CD21⁻ B cells. IA-irAE was further characterized by elevated levels of IL-6, IL-12, and type I IFN, which correlated with the T cell activation phenotypes. Conclusion Altogether, our findings define IA-irAE as a disease with certain immunological features distinctive from RA, representing a potentially T cell driven, autoantibody-independent autoimmunity. These results offer insights into immune tolerance breakdown and therapeutic targeting in irAEs. Funding Source National Institute of Arthritis and Musculoskeletal and Skin Diseases Mark E. and Mary A. Davis Initiative in Rheumatoid Arthritis Research Mayo Foundation for Medical Education and Research Topic Categories Basic Autoimmunity (BA)
ACLY integrates metabolism and chromatin accessibility to enable B Cell activation and humoral immunity
Li, Meilu , Zhang, Zhiqiang , Zhou, Xian, Li, Yanfeng, Zhu, Xingxing , Bhagwate, Aditya, Nagaraj, Nagaswaroop Kengunte , Zeng, Hu , Zeng, Hu , Zhu, Xingxing

Mayo Clinic

No container title available | May 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.24.727510 | PMID 42244640 Get It

Abstract B cell activation and differentiation into antibody-secreting cells require extensive metabolic and epigenetic remodeling, yet the molecular mechanisms that integrate these programs remain incompletely understood. ATP-citrate lyase (ACLY) links glucose metabolism to acetyl-CoA production, supporting lipid biosynthesis and protein acetylation. However, its role in humoral immunity has not been fully defined. Here, using genetic and integrated multi-omics approaches, we show that B cell activation is accompanied by coordinated metabolic, transcriptional, and epigenetic reprograming. Although ACLY is dispensable for B cell development and homeostasis, it is required to establish chromatin accessibility programs in activated B cells, with a more pronounced impact on the epigenetic landscape than on transcriptional output. ACLY-deficient B cells exhibit profound defects in TLR and BCR elicited activation, survival and metabolic fitness ex vivo . In vivo , B cell-intrinsic loss of ACLY results in impaired antigen-specific antibody production, associated with reduced germinal center and plasmablast formation, but normal homeostatic proliferation. Deletion of ACLY after B cell activation reduces plasmablast generation in vivo , indicating a continued requirement for ACLY beyond the initial activation phase. Together, these findings identify ACLY as a central regulator that links metabolism to epigenetic programing that supports B cell activation and humoral immunity.
Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies
Zhu, Xingxing, Yu, Yue , Chen, S., Langenfeld, Hannah E., Li, Yanfeng , Wang, Panwen , McCabe, Chantal E. , Hanson, Andrew C. , Sharp, Brenna , Woltzen, Amber, Markovic, Svetomir N. , Davis, John M., Dong, H. C., Crowson, Cynthia S., Thanarajasingam, Uma , Zeng, Hu, Dong, Haidong , Davis, John M. , Zeng, Hu , Zhu, Xingxing , Li, Ying , Zhu, Xingxing , Chen, Shiju, McCabe, Chantal , Hanson, Andrew C , Sharp, Brenna E, Woltzen, Amber , Markovic, Svetomir , Davis, John M , Dong, Haidong , Crowson, CS , Thanarajasingam, Uma , Zeng, Hu , Li, Ying , Li, Ying, Crowson, Cynthia S.

Mayo Clinic

Science Advances | April 1, 2026 | Volume: 12 | Issue: 14 | Pages: No page available

10.1126/sciadv.aea4262 | PMID 41920990 Get It

The underlying immunopathogenesis of inflammatory arthritis (IA) immune-related adverse event (irAE) remains obscure. Unlike rheumatoid arthritis (RA), where autoantibodies and B cell dysfunction are central features, the contribution of humoral immunity to IA-irAE is unclear. Here, we performed immunophenotyping of peripheral blood from patients with IA-irAE and compared them with patients with seronegative RA, immune checkpoint inhibition–treated patients without irAE, and healthy controls. IA-irAE was marked with increased cytotoxic gene expression and metabolic activation in T cells and reduced CXCR3 and CCR6 expression in CD4 + T cells. Contrary to seronegative RA, patients with IA-irAE displayed no substantial elevation in autoantibody levels or atypical CD11c + CD21 − B cells. IA-irAE was further characterized by elevated levels of interleukin-6 (IL-6), IL-12, and type I interferon, which correlated with the T cell activation phenotypes. Together, our findings define IA-irAE as a disease with certain immunological features distinctive from RA, representing a potentially T cell–driven, autoantibody-independent autoimmunity. These results offer insights into immune tolerance breakdown and therapeutic targeting in irAEs.
CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement
Li, Hao , Luo, Jindan , Liang, Huaiyuan , Yanfeng, Bai , Liu, Jiandong , Wei, Ting , Wang, Liguo , Guo, Hongshan , Xia, Dan , Huang, Haojie , Sun, Rui , Bai, Yanfeng , Wang, Liguo , Huang, Rui , Wei, Ting , Liu, Jiandong , Sun, Rui

Mayo Clinic

Cancer Research | November 25, 2025 | Volume: 86 | Issue: 5 | Pages: 1180-1193

10.1158/0008-5472.can-25-1761 | PMID 41289556 Get It

Abstract CDK12 is frequently deleted and/or mutated in human cancers, and CDK12 inactivation is associated with aggressive phenotypes, including the tendency to metastasis. In this study, we showed that CDK12 deficiency induced intronic polyadenylation (IPA) usage in BRD4 to upregulate expression of the bromodomain-containing protein 4 (BRD4) short isoform (BRD4S). BRD4S demonstrated an enhanced capacity to form phase separation despite lacking the intrinsically disordered region located in the C-terminal of full-length BRD4. Oligomerization of BRD4S mediated phase separation through a base-interacting structural domain. CUT&Tag and RNA sequencing analyses revealed that BRD4S preferentially bound to the promoters of TGFβ signaling genes, including TGFB2 and LTBP1, driving their expression. Consistently, BRD4S drove cancer cell dissemination in vitro and metastasis in vivo, which could be blocked by BET or TGFβ signaling pathway inhibitors. Overall, this study identifies IPA usage at the BRD4 gene locus induced by CDK12 deficiency as a mechanism responsible for BRD4S genesis, which represents an important mechanism driving cancer metastasis and a potential target for therapeutic intervention in CDK12-deficient cancers. Significance: The CDK12–BRD4S–TGFβ signaling axis represents a key regulatory module that promotes metastatic progression and can be targeted by BET or TGFβ pathway inhibitors for treating CDK12-deficient cancers.
The nutrient-sensing Rag-GTPase complex in B cells controls humoral immunity via TFEB/TFE3-dependent mitochondrial fitness 2091
Wu, Yue , Li, Yanfeng , Sun, Jie , Zhu, Xingxing , Zhou, Xian , Shapiro, Virginia Smith , Sun, Jie , Boothby, Mark Robin , Zeng, Hu

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.055 Get It

Abstract Description During the humoral immune response, B cells undergo rapid metabolic reprogramming with a high demand for nutrients, which are vital to sustain the formation of the germinal centers (GCs). Rag-GTPases sense amino acid availability to modulate the mechanistic target of rapamycin complex 1 (mTORC1) pathway and suppress transcription factor EB (TFEB) and transcription factor enhancer 3 (TFE3). However, how Rag-GTPases coordinate amino acid sensing, mTORC1 activation, and TFEB/TFE3 activity in humoral immunity remains undefined. Here, we show that B cell-intrinsic Rag-GTPases are critical for the development and activation of B cells. RagA/RagB deficient B cells fail to form GCs, produce antibodies, and generate plasmablasts in both T-dependent (TD) and T-independent (TI) humoral immune responses. Deletion of RagA/RagB in GC B cells leads to abnormal dark zone (DZ) to light zone (LZ) ratio and reduced affinity maturation. Mechanistically, the Rag-GTPase complex constrains TFEB/TFE3 activity to prevent mitophagy dysregulation and maintain mitochondrial fitness in B cells, which are independent of canonical mTORC1 activation. TFEB/TFE3 deletion restores B cell development, GC formation in Peyer’s patches and TI humoral immunity, but not TD humoral immunity in the absence of Rag-GTPases. Collectively, our data establish Rag-GTPase-TFEB/TFE3 pathway as an mTORC1 independent mechanism to coordinating nutrient sensing and mitochondrial metabolism in B cells. Funding Sources National Institute of Allergy and Infectious Diseases (NIAID) - AI162678 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - AR077518 Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)
The chromatin regulator HELLS mediates SSB repair and responses to DNA alkylation damage
Joseph, Joyous T. , Wright, Christine, Shibata, Etsuko, Khan, Asad Ullah , Neidigk, Jason S Romero, Chen, Bo-Ruei , Tufail, Saba, Mujawar, Aaiyas , Decker, Olivia, Kadali, Krishna Reethika, Imtiaz, Azait, Jones, Brianna A, Zhang, Yanfeng , Gradilone, Sergio A. , Lewis, Zachary , Sen, Arko , Dutta, Anindya , Czaja, Wioletta , Dutta, Anindya , Czaja, Wioletta , Gradilone, Sergio A , Peixoto, Estanislao , Li, Yong , Neidigk, Jason Romero , Imtiaz, Azait, Jones, Brianna A, Lewis, Zachary , Contreras-Galindo, Rafael

Mayo Clinic

Nucleic Acids Research | October 21, 2025 | Volume: 53 | Issue: 22 | Pages: No page available

10.1093/nar/gkaf1201 | PMID 41297801 Get It

Abstract The SNF2 family chromatin remodeler HELLS has emerged as an important regulator of cell proliferation, genome stability, and several cancer pathways. Significant upregulation of HELLS has been reported in 33 human cancer types. While HELLS has been implicated in DNA damage response, its function in DNA repair is poorly understood. Here, we report a new regulatory link between HELLS and single-strand break (SSB) repair in cellular responses to DNA alkylation damage. We found that loss of HELLS impairs SSB repair and selectively sensitizes cells to DNA alkylating agents and PARP inhibitors (PARPi). Our data reveal non-epistatic interactions between HELLS and PARP1 and suggest that HELLS functionally compensates for PARP1 deficiency in promoting cell survival in response to DNA alkylation damage. Furthermore, we found that HELLS is co-expressed with PARP1 in cancer cells, and its loss is synthetic lethal with homologous recombination deficiency (HRD). This work unveils new functions of HELLS in modulating SSB repair and responses to clinically relevant DNA alkylation damage, thus offering new insights into the potential therapeutic value of targeting HELLS in cancer.
RETRACTED: Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in systemic lupus erythematosus
Ai, Minji , Jafar‐Nejad, Paymaan , Li, Yanfeng , Gades, Naomi M. , Alexander, Mariam P., Duarte‐García, Alí , Zeng, Hu , Alexander, Mariam P. , Gades, Naomi, Alexander, Mariam P , Bautista-Vargas, Mario, Duarte-García, Alí , Zeng, Hu , Zhou, Xian , Carrer, Michele , Bautista-Vargas, Mario Alejandro

Mayo Clinic

Rheumatology | December 3, 2024 | Volume: 64 | Issue: 6 | Pages: 3964-3974

10.1093/rheumatology/keae662 | PMID 39656824 Get It

CPT2-mediated Fatty Acid Oxidation Is Dispensable for Humoral Immunity
Li, Meilu , Zhou, Xian , Li, Yanfeng , Zhu, Xingxing , Hitosugi, Taro , Zeng, Hu , Hitosugi, Taro , Zeng, Hu , Zhu, Xingxing , Li, Yanfeng, Li, Yuzhen

Mayo Clinic

The Journal of Immunology | September 11, 2024 | Volume: 213 | Issue: 8 | Pages: 1139-1149

10.4049/jimmunol.2400285 | PMID 39258879 Get It

Abstract B cell activation is accompanied by dynamic metabolic reprogramming, supported by a multitude of nutrients that include glucose, amino acids, and fatty acids. Although several studies have indicated that fatty acid mitochondrial oxidation is critical for immune cell functions, contradictory findings have been reported. Carnitine palmitoyltransferase II (CPT2) is a critical enzyme for long-chain fatty acid oxidation in mitochondria. In this study, we test the requirement of CPT2 for humoral immunity using a mouse model with a lymphocyte-specific deletion of CPT2. Stable [13C] isotope tracing reveals highly reduced fatty acid–derived citrate production in CPT2-deficient B cells. Yet, CPT2 deficiency has no significant impact on B cell development, B cell activation, germinal center formation, and Ab production upon either thymus-dependent or -independent Ag challenges. Together, our findings indicate that CPT2-mediated fatty acid oxidation is dispensable for humoral immunity, highlighting the metabolic flexibility of lymphocytes.
PP2A catalytic subunit alpha is critically required for CD8 + T‐cell homeostasis and antibacterial responses
Li, Meilu , Ai, Minji , Li, Yanfeng , Zhu, Xingxing, Hansen, Michael J. , Zhong, Jun , Johnson, Kenneth L. , Pease, Larry R. , Zeng, Hu , Zhong, Jun , Zenka, Roman, Zeng, Hu , Zhou, Xian , Zenka, Roman M. , Pandey, Akhilesh

Mayo Clinic

European Journal of Immunology | July 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/eji.202451080 | PMID 39072720 Get It

Abstract Although the functions of tyrosine phosphatases in T‐cell biology have been extensively studied, our knowledge on the contribution of serine/threonine phosphatases in T cells remains poor. Protein phosphatase 2A (PP2A) is one of the most abundantly expressed serine/threonine phosphatases. It is important in thymocyte development and CD4 + T‐cell differentiation. Utilizing a genetic model in which its catalytic subunit alpha isoform (PP2A Cα) is deleted in T cells, we investigated its contribution to CD8 + T‐cell homeostasis and effector functions. Our results demonstrate that T‐cell intrinsic PP2A Cα is critically required for CD8 + T‐cell homeostasis in secondary lymphoid organs and intestinal mucosal site. Importantly, PP2A Cα–deficient CD8 + T cells exhibit reduced proliferation and survival. CD8 + T‐cell antibacterial response is strictly dependent on PP2A Cα. Expression of Bcl2 transgene rescues CD8 + T‐cell homeostasis in spleens, but not in intestinal mucosal site, nor does it restore defective antibacterial responses. Finally, proteomics and phosphoproteomics analyses reveal potential targets dependent on PP2A Cα, including mTORC1 and AKT. Thus, PP2A Cα is a key modulator of CD8 + T‐cell homeostasis and effector functions.
Rag-GTPase-TFEB/TFE3 axis controls B cell mitochondrial fitness and humoral immunity independent of mTORC1
Zeng, Hu , Zhu, Xingxing , Wu, Yue , Li, Yanfeng , Chen, Yin , Raybuck, Ariel , Billadeau, Daniel D. , Shapiro, Virginia Smith , Zhu, Xingxing , Wu, Y , Watzlawik, Jens O. , Chen, Yin Maggie, Shapiro, Virginia S , Sun, Jie , Zeng, Hu , Zhou, Xian , Springer, Wolfdieter , Sun, Jie , Boothby, Mark Robin

Mayo Clinic

No container title available | March 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3957355/v1 | PMID 38585731 Get It

Abstract During the humoral immune response, B cells undergo rapid metabolic reprogramming with a high demand for nutrients, which are vital to sustain the formation of the germinal centers (GCs). Rag-GTPases sense amino acid availability to modulate the mechanistic target of rapamycin complex 1 (mTORC1) pathway and suppress transcription factor EB (TFEB) and transcription factor enhancer 3 (TFE3), members of the microphthalmia (MiT/TFE) family of HLH-leucine zipper transcription factors. However, how Rag-GTPases coordinate amino acid sensing, mTORC1 activation, and TFEB/TFE3 activity in humoral immunity remains undefined. Here, we show that B cell-intrinsic Rag-GTPases are critical for the development and activation of B cells. RagA/RagB deficient B cells fail to form GCs, produce antibodies, and generate plasmablasts in both T-dependent (TD) and T-independent (TI) humoral immune responses. Deletion of RagA/RagB in GC B cells leads to abnormal dark zone (DZ) to light zone (LZ) ratio and reduced affinity maturation. Mechanistically, the Rag-GTPase complex constrains TFEB/TFE3 activity to prevent mitophagy dysregulation and maintain mitochondrial fitness in B cells, which are independent of canonical mTORC1 activation. TFEB/TFE3 deletion restores B cell development, GC formation in Peyer’s patches and TI humoral immunity, but not TD humoral immunity in the absence of Rag-GTPases. Collectively, our data establish Rag-GTPase-TFEB/TFE3 axis as an mTORC1 independent mechanism to coordinating nutrient sensing and mitochondrial metabolism in B cells.